Aster DM Healthcare Limited, one of the largest private healthcare service providers operating in multiple GCC states has setup first-of-its-kind “clinical simulation lab” to give boost to clinical real-world evidence across India and Middle East. The brand has partnered with THB c/o Sekhmet Technologies – a leading real world evidence company across India, GCC, and SEA – to drive data transformation and to deliver clinical evidence and research.
Amidst nearly 100mn Covid-19 cases globally (10mn+ cases in India), there is finally a ray of hope in front of us in the form of the approved vaccines. While clinical trials across the globe are showing promising results from these vaccines, the quantum of patients enrolled across these trials as well as the overall timeline are both insignificant to confirm the effectiveness and safety across every patient group. When multiple dimensions of age, gender, existing diseases, Covid-19 infection history, smoking habits, race, location, and many more are combined, the permutation of possible patient groups run in hundreds.
The silver lining to 10mn+ cases in India is that there is potentially that much real-world data to study on how Covid-19 has impacted different patient groups. And likewise, as the vaccination drive accelerates, data on millions of patients across different patient groups will be generated. This large quantum of data will provide answers to questions that time bound clinical trials across smaller number of subjects may not be able to provide. The science of leveraging data from the day-to-day clinical practices – also called Real World Evidence – has the power to what eventually is wanted to achieve – Covid-19 eradication.
Dr. Satish Prasad Rath, Chief Innovation & Research Officer at Aster DM Healthcare shared that Aster has setup first-of-its-kind “clinical simulation lab” to give boost to clinical real-world evidence across India and Middle East. Real world evidence is the need of the hour to study drug efficacy and safety, discover repurposed drugs and drive interventions for personalized patient care and treatment. This needs advanced use of AI, for which, Aster Group has partnered with THB c/o Sekhmet Technologies – a leading real world evidence company across India, GCC, and SEA – to drive data transformation and to deliver clinical evidence and research. “At our scale, and our focus on paperless facilities, we are compiling and analyzing millions of datasets to understand the behavior of a series of diseases, and the treatment outcomes across patient groups”, says Dr. Rath.
Akansh Khurana, CEO of THB mentioned that they are in the process of setting up the foundation to collect and compile anonymized data on Covid-19 vaccines usage and the associated short-term as well as long-term outcomes. “We have published extensive medical research across a range of diseases, including Covid-19, and one of our key focus areas over 2021 and 2022 is to continue to compile data on Covid-19 and support the regulators, and the healthcare industry with granular and long-term datasets on the disease, its treatment pathways and vaccinations”, says Mr. Khurana.